

Form PTO-1390  
P20637.P02

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

100 Rec'd PCT/PIO 16 FEB 2001  
ATTORNEY'S DOCKET NUMBER

P20637

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/744989

INTERNATIONAL APPLICATION NO.

PCT/JP99/04479

INTERNATIONAL FILING DATE

20 August 1999

PRIORITY DATE CLAIMED

20 August 1998

TITLE OF INVENTION

EPIMORPHIN OF THE ORDER ARTIODACTYLA

APPLICANT(S) FOR DO/EO/US

K. TSUGANEZAWA

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. ☒ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3))
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).  
"UNEXECUTED"
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (U.S.C. 371(c)(5)).

Items 11 to 16 below concern other document(s) or information included:

11. Assignee: Sumitomo Electric Industries, Ltd., of Osaka, JAPAN
12. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
13. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
14. ☒ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ Figure of Drawing to be published \_\_\_\_\_
18. ☒ Other items or information:


PCT Request with International Application as filed (in Japanese).  
International Application as published (in Japanese).  
PCT/ISA/210 (in Japanese and English).  
PCT/IPEA/409 International Preliminary Examination Report (in Japanese).  
PCT/IPEA/408 Written Opinion (in Japanese).  
PCT/IB/304.  
PCT/IB/301.  
PCT/IB/332.  
PCT/IB/308.  
Diskette Containing Sequence Listing.  
Claim of Priority.

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="font-size: 24pt; font-weight: bold; text-align: center;">091 / 44989</div>		INTERNATIONAL APPLICATION NO. PCT/JP99/04479		ATTORNEY'S DOCKET NUMBER P20637	
---	--	---	--	------------------------------------	--

19. <input checked="" type="checkbox"/> The following fees are submitted:  <div style="margin-left: 40px;">           Basic National Fee (37 CFR 1.492(a)(1)-(5)):             Search report has been prepared by the EPO or JPO. . . . . \$ 860.00            International preliminary examination fee paid to USPTO (37 CFR 1.482). . . . . \$ 690.00            No international preliminary examination fee paid to USPTO (37 CFR 1.482) but            international search fee paid to USPTO(37 CFR 1.445(a)(2)). . . . . \$ 710.00            Neither international preliminary examination fee (37 CFR 1.482) nor            international search fee (37 CFR 1.445(a)(2) paid to USPTO. . . . . \$1,000.00            International preliminary examination fee paid to USPTO (37 CFR 1.482) and all            claims satisfied provisions of PCT Article 33(2)-(4). . . . . \$ 100.00   <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div> </div>				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 50%;">CALCULATIONS</th> <th style="width: 50%;">PTO USE ONLY</th> </tr> <tr><td style="height: 100px;"></td><td></td></tr> </table>		CALCULATIONS	PTO USE ONLY		
CALCULATIONS	PTO USE ONLY								
Surcharge of \$130.00 for furnishing the oath or declaration later than ___ 20 ___ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 0.00					
Claims	Number Filed	Number Extra	RATE	\$ 0.00					
Total Claims	11 - 20 =	0	X \$18.00	\$ 0.00					
Independent Claims	6 - 3 =	3	X \$80.00	\$ 240.00					
Multiple dependent claim(s) (if applicable)				+ \$270.00	\$ 0.00				
TOTAL OF ABOVE CALCULATIONS =				\$ 1,100.00					
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 0.00					
SUBTOTAL =				1,100.00					
Processing fee of \$130.00 for furnishing the English translation later than ___ 20 ___ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	0.00				
Extension of Time fee in the amount of \$				0.00					
TOTAL NATIONAL FEE =				1,100.00					
Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	0.00				
TOTAL FEES ENCLOSED =				1,100.00					
				Amount to be refunded	\$				
				Charged	\$				

a. <input checked="" type="checkbox"/> A check in the amount of <u>\$1,100.00</u> to cover the above fees is enclosed. b. ___ Please charge my Deposit Account No. ___ in the amount of \$___ to cover the above fees. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0089</u> .	<div style="font-size: 24pt; font-family: cursive;">  </div> <div style="font-size: 12pt;">             SIGNATURE  <u>Bruce H. Bernstein</u>              NAME   <u>29.027</u>              REGISTRATION NUMBER           </div>
--	---

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.  
  
 SEND ALL CORRESPONDENCE TO CUSTOMER NO. 7055  
 AT THE PRESENT ADDRESS OF:  
  
 Bruce H. Bernstein  
 GREENBLUM & BERNSTEIN, P.L.C.  
 1941 Roland Clarke Place  
 Reston, VA 20191  
 (703) 716-1191

P20637

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : K. TSUGANEZAWA

Serial No :Not Yet Assigned  
(U.S. National Phase of PCT/JP99/04479)

Filed :Concurrently Herewith

For : EPIMORPHIN OF THE ORDER ARTIODACTYLA

**COVER LETTER ACCOMPANYING U.S. NATIONAL STAGE PATENT  
APPLICATION FILED UNDER 35 U.S.C. 371  
AND 37 C.F.R. 1.495**

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:


Enclosed is a new National Stage patent application for filing in the U.S. Patent and Trademark Office under 35 U.S.C. 371 and 37 C.F.R. 1.495. The Declaration and Power of Attorney attached thereto are in unexecuted form. A properly executed Declaration and Power of Attorney, will be filed within the period of time set in a Notification to be mailed by the United States Patent and Trademark Office.

Related to this, a correspondence address is provided in the unexecuted Declaration and Power of Attorney, and is as follows:

GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, Va. 20191

If there any questions pertaining to this National Stage Application, the please contact the undersigned below.

Respectfully submitted,  
K. TSUGANEZAWA

  
Bruce H. Bernstein  
Reg. No. 29,027

February 16, 2001  
GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

*4/20/01 33.094*

0944499-0044  
"63647260"

P20637

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : K. TSUGANEZAWA

Serial No : Not Yet Assigned

Filed : Concurrently Herewith

For : EPIMOROHIN OF THE ORDER ARTIODACTYLA

**PRELIMINARY AMENDMENT**

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

Prior to the examination of the above-identified patent application, the Examiner is respectfully requested to amend the specification and claims as follows:

IN THE CLAIMS

Please amend the claims as follows:

In claim 9, line 1, please change "any one of claims 1 to 8" to ---claim 1---.


In claim 11, line 1, please change "any one of claims 1 to 8" to ---claim 1---.

REMARKS

The Examiner is respectfully requested to enter the foregoing amendment prior to examination and calculation of the filing fees in the above-identified patent application.

Should there be any questions, the Examiner is invited to contact the undersigned at the below listed number.

Respectfully submitted,  
K. TSUGANEZAWA

  
\_\_\_\_\_  
Bruce H. Bernstein  
Reg. No. 29,027

February 16, 2001  
GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

P20637.A02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : K. TSUGANEZAWA

Art Unit: UNKNOWN

Appl. No. : 09/744,989

Examiner: UNKNOWN

I. A. Filed : August 20, 1999

For : EPIMORPHIN OF THE ORDER ARTIODACTYLA

## SUPPLEMENTAL PRELIMINARY AMENDMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Further to the Preliminary Amendment filed February 16, 2001, and prior to an examination of the above-identified patent application, the Examiner is respectfully requested to amend the application as follows:

IN THE SPECIFICATION

Please replace the sequence listing section filed with the application, i.e., pages 1-8, with the sequence listing being filed herewith, i.e., pages 1-6.

REMARKS

The Examiner is respectfully requested to enter the foregoing amendment prior to examination of the above-identified patent application.

P20637.A02

Since the differences between the sequence listing filed herewith and the sequence listing filed with the application on February 16, 2001 are discussed in the Cover Letter Accompanying Sequence Listing filed herewith, a marked-up copy of the sequence listing is not being provided. If a marked-up copy of the sequence listing is necessary, please advise.

If there are any comments or questions, the undersigned may be contacted at the below-listed telephone number.

May 3, 2001  
GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

Respectfully Submitted,  
K. TSUGANEZAWA

*Steven J. Helmer*  
*Reg. No. 40,475*

Bruce H. Bernstein  
Reg. No. 29,027



P20637.A05

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : K. TSUGANEZAWA

Art Unit: UNKNOWN

Appl. No. : 09/744,989

Examiner: UNKNOWN

I. A. Filed : August 20, 1999

For : EPIMORPHIN OF THE ORDER ARTIODACTYLA

**SUPPLEMENTAL PRELIMINARY AMENDMENT**Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Prior to an examination of the above-identified patent application, the Examiner is respectfully requested to amend the application as follows:

IN THE SPECIFICATION

Please replace the Sequence Listing section filed on May 4, 2001, which replaced the Sequence Listing filed with the application, with the Sequence Listing being filed concurrently herewith.


REMARKS

The Examiner is respectfully requested to enter the foregoing amendment prior to examination of the above-identified patent application.

P20637.A05

If there are any comments or questions, the undersigned may be contacted at the below-listed telephone number.

Respectfully submitted,  
Keiko TSUGANEZAWA

  
\_\_\_\_\_  
Bruce H. Bernstein  
Reg. No. 29,027

*Re 100  
45,905*

August 24, 2001  
GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke  
Reston, VA 20191  
(703) 716-1191

## SPECIFICATION

## Epimorphin of the order Artiodactyla

## Technical Field

The present invention relates to epimorphin derived from the order Artiodactyla including pigs, cows, sheep and the like.

## Background Art

Morphology of various organs of animals is constructed by epithelial tissues, and mesenchymal cells exist around the tissues. An epimorphin is a cell membrane protein that is expressed in mesenchymal cells, particularly in a high amount neighboring epithelial cells (Hirai, Y., et al., Cell, 69, pp.471-481, 1992). It is considered that the progress of morphogenesis of the epithelial tissue requires a signal from the mesenchymal cells (Gumbiner, B.M., Cell., 69, pp.385-387, 1992). Epimorphins have been cloned in humans, birds, and rats as well as in mice. The presences of isoforms are known which have a different sequence of a hydrophobic site (Zha, H., et al., Genomics, 37, pp. 386-389, 1996; Hirai, Y., et al., Biochem. Biophys. Res. Commun., 191, p. 1332-1337, 1993; Oka, Y., Developmental Biological Society, 1997, May).

Epimorphin is known to be deeply involved in morphogenesis by epithelial tissues in mice, i.e., differentiation into hair on the fetal talon skin, and differentiation into luminal structure in the fetal lung (Hirai, Y., et al., Cell, 69, pp.471-481, 1992; Koshida, S., et al., Biochem. Biophys. Res. Commun., 234, pp. 522-525, 1997). Moreover, epimorphin activates mesenchymal cells and promotes secretion of cytokines, IL-6 and IL-8 (Oka, Y., et al., Exp. Cell Res., 222, pp. 189-198, 1996). Recently, it was revealed that the addition of epimorphin to milk protein-producing SCp2 cells induces cell growth to form a branched duct structure (Hirai, Y., et al., J. cell Biol., 140, pp. 159-169, 1998). Epimorphin is expected to be effective in elucidating the mechanism of onset of diseases due to abnormality of organs, developing methods for diagnosing and treating said diseases, generating hairs, lumens, bones, and teeth, generating new blood vessels, and developing new

methods for treatment of injuries (Zha, H., et al., Genomics, 37, pp.386-389, 1996; Panaretto, B.A., Reprod. Fertil. Dev., 5, pp. 345-360, 1993; Matsuki, Y., et al, Archs. Oral Biol., 40, pp. 161-164, 1995).

#### Disclosure of the Invention

A so-called animal factory, which allows an animal to secrete a desired protein in its milk, has recently been used practically. Mammals of the order Artiodactyla including cows and sheep are often utilized as animals for the secretion of a desired protein in milk. However, particularly when a desired protein has a relatively large molecular weight or when the secretion amount of a desired protein becomes high, mammary glands may often clog and the desired protein cannot be extracorporeally recovered. Accordingly, for practical application of an effective animal factory, it is required that means be developed which enlarges the mammary glands of such animals and prevents the mammary glands of the animals from clogging even when a large amount of the desired protein is produced in the milk.

The inventors of the present invention have focused on the fact that epimorphin induces differentiation of SCp2 cells into a branched duct structure, and conducted various studies to isolate an epimorphin gene of Artiodactyls. As a result, the inventors have succeeded in the isolation of an epimorphin gene derived from an animal belonging to Artiodactyls, and found that the gene product has an activity of enlarging mammary glands, i.e., an activity of differentiating mammary cells so as to enlarge the internal diameters of the ducts. The present invention was achieved on the basis of these findings.

The present invention thus provides a protein comprising an amino acid sequence set forth in SEQ ID NO: 1 in the Sequence Listing (also referred to as "bovine epimorphin 2"), a protein comprising an amino acid sequence set forth in SEQ ID NO: 3 in the Sequence Listing (also referred to as "bovine epimorphin 4"), and a protein comprising an amino acid sequence set forth in SEQ ID NO:5 in the Sequence Listing (also referred to as "sheep epimorphin 2"). The present invention also provides a protein having 95 % or more homology to an amino acid sequence from the 1st to 262nd amino acids set forth in SEQ ID NO: 1 (bovine epimorphin 2) in the Sequence Listing; a protein having an amino acid sequence from the 1st to 262nd

amino acids set forth in SEQ ID NO: 1 in the Sequence Listing; and a protein having an amino acid sequence from the 1st to 262nd amino acids set forth in SEQ ID NO: 5 in the Sequence Listing.

The invention further provides a protein having any one of the amino acid sequences set forth in SEQ ID NOS: 1, 3, and 5 in the Sequence Listing wherein one or more amino acids are substituted, deleted, and/or added, and inducing differentiation of milk protein-producing cells derived from mammals, preferably those derived from Artiodactyla, into a branched luminal structure; and a protein having any one of the amino acid sequences of SEQ ID NOS: 1, 3, and 5 in the Sequence Listing wherein one or more amino acids are substituted, deleted, and/or added, and promoting hair growth in mammals, preferably in Artiodactyls.

Furthermore, the present invention provides a protein in which one or more amino acids are substituted, deleted, and/or added in an amino acid sequence defined by the 1st to 262nd amino acids of either of the amino acid sequence set forth in SEQ ID NOS: 1 or 5 in the Sequence Listing, which has 95 % or more homology to the amino acid sequence defined by the 1st to 262nd amino acids of either of the amino acid sequence set forth in SEQ ID NO: 1 or 5 and induces differentiation of milk protein-producing cells into a branched luminal structure; and a protein in which one or more amino acids are substituted, deleted, and/or added in an amino acid sequence defined by the 1st to 262nd amino acids of either of the amino acid sequence set forth in SEQ ID NOS: 1 or 5 in the Sequence Listing, which has 95 % or more homology to the amino acid sequence defined by the 1st to 262nd amino acids of either of the amino acid sequence set forth in SEQ ID NO: 1 or 5 and promotes hair growth.

From another aspect, the present invention provides a polynucleotide encoding each of the above-mentioned proteins. According to preferred embodiments of the invention, DNAs set forth in SEQ ID NOS: 2, 4, and 6 are provided. The invention also provides a DNA comprising continuous 12 or more nucleotides contained in said nucleotide sequences in the Sequence Listing. The DNA may be either double- or single-strand, and may be either a sense or antisense strand when the DNA is single-stranded. Furthermore, the invention provides RNA hybridizing to the above DNA, and a polynucleotide as being the above polynucleotide with chemical modification.

The present invention also provides a recombinant vector having the aforementioned polynucleotide, a transformant such as a microbial cell and a mammalian cell which comprises said vector, and a process of producing the above proteins which comprises the steps of isolating and purifying the protein from a culture obtained by cultivation of said transformant. The present invention further provides an antibody, preferably a monoclonal antibody, recognizing each of the above proteins.

#### Best Mode for Carrying out the Invention

Three isoforms of epimorphins are known to exist (Hirai, Y., et al., J. Cell Biol., 140, pp. 159 – 169, 1998). These isoforms are classified as isoforms 1, 2 and 3, based on the number of amino acids at the C-terminal portion and their properties (hydrophobicity or hydrophilicity). According to this classification, bovine epimorphin 2 comprising an amino acid sequence set forth in SEQ ID NO: 1 in the Sequence Listing, and sheep epimorphin 2 comprising an amino acid sequence set forth in SEQ ID NO: 5 in the Sequence Listing, which are preferable examples of the present invention, are both classified as isoform 2. Bovine epimorphin 4 comprising an amino acid sequence set forth in SEQ ID NO: 3 in the Sequence Listing fails to comply with any one of the above classifications and is recognized as a new type of isoform.

Structurally, epimorphins can be divided into four domains. Also in the specification, epimorphins of the present invention are structurally divided into four portions, each referred to as domain 1, domain 2, domain 3, and domain 4 in the order from the N-terminal side. Domains 1 to 4 of the above-mentioned bovine epimorphin 2, bovine epimorphin 4, and sheep epimorphin 2 are as follows (an amino acid sequence set forth in SEQ ID NO:1 in the Sequence Listing will be simply referred to as "Amino acid sequence 1", which will apply to all the other sequences).

#### Bovine epimorphin 2

Domain 1: 1st to 107th amino acids of amino acid sequence 1

Domain 2: 108th to 187th amino acids of amino acid sequence 1

Domain 3: 188th to 262nd amino acids of amino acid sequence 1

Domain 4: 263rd to 287th amino acids of amino acid sequence 1

#### Bovine epimorphin 4

Domain 1: 1st to 107th amino acids of amino acid sequence 3

Domain 2: 108th to 187th amino acids of amino acid sequence 3

Domain 3: 188th to 262nd amino acids of amino acid sequence 3

Domain 4: 263rd to 269th amino acids of amino acid sequence 3

#### Sheep epimorphin 2

Domain 1: 1st to 107th amino acids of amino acid sequence 5

Domain 2: 108th to 187th amino acids of amino acid sequence 5

Domain 3: 188th to 262nd amino acids of amino acid sequence 5

Domain 4: 263rd to 287th amino acids of amino acid sequence 5

Domains 1 and 3 are coiled coil regions referred to as "a coiled coil region on the N side" and "a coiled coil region on the C side", respectively. Domain 4 is a hydrophobic domain referred to as the C-terminal hydrophobic region. Each of these domains is known to have the following functions, based on the findings about human and mouse epimorphin.

Domain 1: Promotion of differentiation into hair on the fetal talon skin, differentiation into luminal structure in the fetal lung, activation of mesenchymal cells, and promotion of secretion of cytokines, IL-6 and IL-8.

Domain 2: Cell adhesion and promotion of secretion of GM-CSF (a growth factor, a type of cytokine)

Domain 3: Function unknown

Domain 4: Type 1 cell membrane binding domain

Functions of Domains 1 and 2 are engaged in promotion of differentiation of milk protein-producing cells into luminal structure. Functions of epimorphins and their domains can be determined by methods described in publications. The present invention further encompasses polypeptides corresponding to each of the domains

explained as for bovine epimorphin 2, bovine epimorphin 4, and sheep epimorphin 2; and a polypeptide having one of the amino acid sequences of each of these domains, in which one or more amino acids are substituted, deleted, and/or added, and having a biological action substantially the same as that of each of the domains.

As for the above three types of epimorphin, the amino acid sequence from the 1st to 262nd amino acids of the bovine epimorphin 2 is completely identical to that from the 1st to 262nd amino acids of bovine epimorphin 4. Furthermore, this sequence has 99.2 % homology to the sequence from the 1st to 262nd amino acids of sheep epimorphin 2 and the sequences are well conserved. Therefore, the region of the amino acid sequences is a characteristic amino acid sequence for Artiodactyla epimorphin, and a protein comprising said amino acid sequence is a preferred embodiment of the present invention. Any proteins having homology of 95 % or more, preferably 98 % or more, with the amino acid sequence from the 1st to 262nd amino acids of the bovine epimorphin 2, and having a function substantially equivalent to that of the above amino acid sequence fall within the scope of the present invention. In addition, sheep epimorphin 2 and human epimorphin have 94.3 % homology in an amino acid sequence from the 1st to 262nd amino acids, which are also well conserved. The term "homology" herein used means the maximum value obtained by subjecting one amino acid sequence to alignment based on the other sequence where the two sequences are compared. Such alignment can be conducted conveniently by using a commercially available computer software. An example of the software includes Genetics-Mac sold by Software Developing Co., Ltd.

The present invention also encompasses within the scope a protein having any one of the amino acid sequences set forth in SEQ ID NOS: 1, 3, and 5 in the Sequence Listing, in which one or more amino acids are substituted, deleted and/or added, and inducing differentiation of milk protein-producing cells into branched luminal structure; and a protein having any one of the amino acid sequences set forth in SEQ ID NOS: 1, 3, and 5 in the Sequence Listing, in which one or more amino acids are substituted, deleted and/or added, and promoting hair growth (these proteins are herein also referred to as "modified proteins" and where "protein(s) of the present invention" is referred to, the description is used to also encompass these modified proteins unless otherwise specifically mentioned). The action of inducing



differentiation of milk protein-producing cells into branched luminal structure can be determined by methods described in J. Cell Biol., 140, pp. 159-169, 1998. It is also recognized that known epimorphins have hair growth promoting action (Hirai, Y., et al., Cell, 69, pp. 471-481, 1992).

These modified proteins can be produced by treating Escherichia coli having a DNA encoding any one of the amino acid sequences set forth in SEQ ID NOS: 1, 3 and 5 with an agent such as N-nitro-N'-nitro-N-nitrosoguanidine to cause mutation, recovering a gene encoding a modified protein from the bacterial cells; and performing an ordinary gene expression. In addition, the gene may be directly treated with an agent such as sodium sulfate, or nucleotide deletions, substitutions or additions may be directly introduced into the gene by techniques such as site-specific mutation method (Kramer, W. et al., Methods in Enzymology, 154, 350, 1987) and recombinant PCR method (PCR Technology, Stockton press, 1989).

Methods to obtain genes encoding the protein of the present invention are not particularly limited. For example, a genetic DNA can be efficiently recovered by methods specifically described in the examples of the specification. It is well known to persons skilled in the art that, due to degeneracy of genetic codes, at least a part of nucleotides of the nucleotide sequence of the polynucleotide can be replaced with other types of nucleotides without changing the amino acid sequence of the polypeptide produced based on the polynucleotide. Therefore, the polynucleotides of the present invention encompass any epimorphin genes encoding any one of the amino acid sequences set forth in SEQ ID NOS: 1, 3, and 5. As preferable examples of the genes of the present invention, DNAs encoding bovine epimorphin 2, bovine epimorphin 4, and sheep epimorphin 2 are shown in SEQ ID NOS: 1, 4, and 6, respectively.

Antisense polynucleotides and derivatives thereof also fall within the scope of the present invention, which have a nucleotide sequence of an antisense strand of the polynucleotide encoding the protein of the present invention. Although the antisense polynucleotides are provided as a class of an embodiment of the aforementioned polynucleotides, the polynucleotides may also be herein referred to as "antisense polynucleotides" to specify that they are polynucleotides particularly having a nucleotide sequence of an antisense strand. The antisense polynucleotide can

hybridize to a polynucleotide encoding each of the above proteins, and where a polynucleotide to which the antisense polynucleotide hybridizes is a polynucleotide in a coding region, biosynthesis of a polypeptide encoded by said polynucleotide can be inhibited.

An antisense polynucleotide for inhibiting the biosynthesis of the polypeptide preferably comprises 12 or more nucleotides, further preferably comprises 16 or more nucleotides. An unnecessarily long sequence is not preferred to achieve incorporation of the full length of an antisense polynucleotide into cells. For intracellular incorporation of the antisense polynucleotide to induce inhibition of the biosynthesis of the above proteins, the antisense polynucleotides comprising 12 to 30 nucleotides, preferably 15 to 25 nucleotides, more preferably 18 to 22 nucleotides may preferably be used.

The antisense polynucleotides or derivatives thereof of the present invention encompass any of those comprising multiply bound nucleotides each consisting of a base, a phosphoric acid, and a sugar, regardless of they are naturally or non-naturally derived. Typical examples include a natural antisense DNA and antisense RNA. Examples of non-natural polynucleotides include methylphosphonate-type and phosphorothioate type polynucleotides. Various antisense polynucleotide derivatives having excellent abilities of binding to a target DNA or mRNA, tissue specificity, cell-permeability, nuclease resistance, and intracellular stability can be obtained by applying methods in antisense technology available to persons skilled in the art.

Generally, from a viewpoint of easy hybridization, it is preferable to design antisense polynucleotides and derivatives thereof having a nucleotide sequence complementary to that in a region forming an RNA loop. In addition, an antisense polynucleotide that has a sequence complementary to a sequence of around a translation initiating codon, a ribosome binding site, a capping site, or a splicing site can be expected to have a high suppressing effect on expression. Among the antisense polynucleotides and derivatives thereof, those comprising a sequence complementary to genes encoding each of the above proteins, or to a sequence of around a translation initiation codon by mRNA, a ribosome binding site, a capping site, and/or a splicing site are preferred from a viewpoint of the effect on the suppression of expression.

Among polynucleotide derivatives widely known to date, an example of the derivatives having at least one enhanced abilities of nuclease resistance, tissue specificity, cell-permeability, and binding ability includes a derivative having phosphorothioate bondings as a backbone structure. The polynucleotides and derivatives thereof of the present invention encompass the aforementioned derivatives having these functions or said structure.

Among the antisense polynucleotides of the present invention, natural antisense polynucleotides can be prepared by using a chemical synthesizer, or by carrying out the PCR using a DNA encoding each of the above proteins as a template. The methyl phosphonate-type or phosphorothioate-type polynucleotide derivatives can generally be produced by chemical synthesis. For the synthesis, operations may be conducted according to an instruction manual appended to a chemical synthesizer, and a resulting product synthesized can be purified by a HPLC method using reverse phase chromatography and the like.

The polynucleotide encoding the protein of the present invention, and the antisense polynucleotides or portions thereof (a polynucleotide having a nucleotide sequence which comprises continuous 12 or more nucleotides) can be used as probes for screening the gene of the present invention from a cDNA library or the like. For said purpose, a polynucleotide with a GC content of 30 to 70 % can preferably be used. A polynucleotide having a sequence comprising continuous 16 or more nucleotides may particularly preferred. Derivatives of the polynucleotides may be used as probes. In general, a sequence having nucleotides of the aforementioned number of nucleotides is recognized as a sequence with specificity.

As the cDNA libraries used for the screening with the above probe, those constructed from mRNA may preferably used. A class of cDNAs selected by random sampling from the above cDNA libraries may be used as a sample for the screening. Commercially available libraries may also be used. For example, DNA having a nucleotide sequence comprising a continuous 12 or more nucleotides of the nucleotide sequence set forth in SEQ ID NO: 2, 4 or 6 in the Sequence Listing, or a polynucleotide (antisense polynucleotide) that hybridizes to the DNA can be used as a probe for screening a DNA encoding any one of the amino acid sequences set forth in SEQ ID NOS: 1, 3 and 5 from the cDNA library or the like.

Moreover, a tissue in which an mRNA deriving from the gene of the present invention is expressed can be detected by means of Northern blotting hybridization for mRNAs deriving from various tissues using a polynucleotide encoding the protein of the present invention or an antisense polynucleotides thereof, or a fragment polynucleotide thereof as a probe.

Transformants can be prepared by inserting a cDNA capable of hybridizing to the gene of the present invention into an appropriate vector, and then introducing the recombinant vector into a host (for example, *Escherichia coli*). Types of the vectors and the hosts are not particularly limited, and an appropriate expression vector can be selected depending on the type of the host. As the host, any of bacteria such as *Escherichia coli*, yeast, or animal cells can be used. Animal cells are preferably used, and most preferably, mammal cells may be used. Methods for introducing the recombinant vector into an appropriate host such as *Escherichia coli* to obtain a transformant are not particularly limited. Any technique available to those skilled in the art can be employed.

The protein of the present invention can be produced by culturing the transformant, in which the gene of the present invention is introduced, to allow the cells to amplify the gene DNA or express the protein. A variety of literature and reports are available about the production and culture of transformants, and various techniques have been developed and widely used in the art. Accordingly, those skilled in the art can easily produce the protein of the present invention based on the nucleotide sequences set forth in the specification. As methods for introducing genes into cells, calcium chloride method, protoplast method, electroporation and the like may be used. Nuclear microinjection may be most preferably used.

Separation and purification of the target protein from a culture can be performed by the appropriate combination of techniques available to persons skilled in the art. For example, by performing procedures including concentration, solubilization, dialysis, and various types of chromatographies as required, the protein of the present invention can be efficiently recovered and purified. More specifically, the separation and purification may be carried out by appropriately choosing immunoprecipitation, salting out, ultrafiltration, isoelectric precipitation, gel filtration, electrophoresis, ion exchange chromatography, various affinity

chromatography such as hydrophobic chromatography or antibody chromatography, chromatofocusing, adsorption chromatography, and reverse phase chromatography.

The protein of the present invention can be produced as a fusion peptide with other polypeptide(s). It should be understood that such fusion polypeptides also fall within the scope of the present invention. Types of the polypeptide to be fused are not particularly limited. An example includes a signal peptide which promotes extracellular secretion. The preparation of the fusion protein can also be preformed by using transformants. When the protein or the modified protein of the present invention is produced by using the fusion protein, the fusion protein is treated with a chemical substance such as cyanogen bromide or an enzyme such as a protease, and then the cleaved target product may be separated and purified.

A fusion protein may also be prepared which composes of a partial polypeptide responsible for epimorphin-like biological activities in the protein or modified protein of the present invention (so called an active domain) and other polypeptide. The above-mentioned domain 1 and/or domain 2 can be used as such active domains. For example, a soluble polypeptide containing an active domain can be produced by removing domain 4, and a fusion protein composed of the solubilized active domain and other polypeptide (e.g., a signal peptide) can be produced. A chimeric epimorphin may be produced by appropriately combining plural domains selected from each of the above domains of the protein of the present invention and each of the domains of the other types of epimorphin. Furthermore, a fusion protein may be produced by binding other polypeptide to a polypeptide composed of an appropriate combination of each of the above domains.

An antibody recognizing the protein of the present invention can be produced by using the protein of the present invention or a partial polypeptide chain thereof. The antibody of the present invention can be produced by sensitizing and immunizing a mammal with the protein of the present invention according to methods widely used in the art. Whether or not the antibody can recognize the protein of the present invention is determined by a method such as Western blotting, ELISA, or immunostaining (e.g., measurement by FACS). As immunogens, the protein of the present invention as well as a part of the protein bound to a carrier protein, e.g., bovine serum albumin may be used. The part of the protein of the present invention

may preferably comprise eight or more amino acid residues, and such polypeptide may be synthesized, for example, by using a peptide synthesizer.

A monoclonal antibody generated by a hybridoma which is produced by using lymphocytes of an immunized animal may be used as the antibody of the present invention. Methods for preparing monoclonal antibodies are well known in the art and widely used ("Antibodies A Laboratory Manual, " Cold Spring Harbor Laboratory Press, 1988, Chapter 6). In addition, active fragments of the above antibody can be used as the antibody of the present invention. In the specification, "active fragments" means fragments of an antibody having antigen-antibody reaction activity. More specifically, examples include  $F(ab')_2$ ,  $Fab'$ ,  $Fab$ , and  $Fv$ . For example, where the antibody of the present invention is decomposed with pepsin,  $F(ab')_2$  is obtained; where decomposed with papain,  $Fab$  is obtained. Where  $F(ab')_2$  is reduced with a reagent such as 2-mercaptoethanol and then alkylated with monoiodoacetic acid,  $Fab'$  is obtained.  $Fv$  is a monovalent active antibody fragment composed of a heavy-chain variable region and a light-chain variable region bound with a linker to each other. A chimeric antibody can be obtained by preserving these active fragments and replacing the other part with fragments deriving from other animals. Any of the above described antibodies and active fragments and the like fall within the scope of the present invention.

The protein of the present invention can be detected by a method utilizing an antibody or an enzymatic reaction. Examples of the methods for detecting the protein of the present invention using an antibody include (I) a method for detecting the protein of the present invention using the aforementioned antibody with labeling, and (II) a method for detecting the protein of the present invention using the aforementioned antibody and a labeled secondary antibody recognizing said antibody. As means for labeling, radioactive isotopes (RI), enzymes, avidin or biotin, or fluorescent materials (FITC, rhodamine, and the like) may be utilized. Examples of methods utilizing an enzymatic reaction include ELISA, immunoagglutination, Western blotting, a process for identifying an immunoreactive molecule using flow cytometry and methods similar thereto.

## Examples

The present invention will be explained more specifically by way of examples. However, the scope of the present invention is not limited to the following examples.

The sheep and bovine epimorphin genes of the present invention were obtained by the methods set out below.

### 1. Isolation of epimorphin cDNA

1) DNA to be used as a probe was labeled using Random Primed DNA Labeling Kit (manufactured by Boehringer Mannheim) according to the instructions appended to the kit. DNA comprising the full length of a nucleotide sequence of a mouse epimorphin-coding region was used as a DNA probe.

2) DNA reaction solution having the following composition was then prepared. The solution was incubated for 30 minutes at 37°C, and then heated for 10 minutes at 65°C for inactivation of enzymes.

DNA probe (50 ng/ $\mu$ l)	2 $\mu$ l
H <sub>2</sub> O	7 $\mu$ l
dNTPs	3 $\mu$ l
[ $\alpha$ - <sup>32</sup> P]d - CTP (370MBq/ml) (manufactured by Amersham Pharmacia Biotech)	
5 $\mu$ l	
Primer	2 $\mu$ l
Klenow enzyme	1 $\mu$ l
Total	20 $\mu$ l

3) The reaction solution was centrifuged with a Centri-Sep spin column (manufactured by Princeton Separations, Inc.) swollen with H<sub>2</sub>O, thereby obtaining a labeled DNA probe.

4) Using the sheep lung and cow lung as libraries (Uni-ZAPXR Library, ST, manufactured by STRATAGENE), phage plaques were obtained by a standard method (New Cell Technology Experimental Protocol, Shu-jun sha).

5) The labeled DNA probe obtained in 3) were measured by using a scintillation counter, added to a hybridization reaction solution to  $1 \times 10^6$  cpm/ml.

Then, the product was allowed to react with a nylon membrane to which cDNA derived from the plaque was immobilized (Hybond - N+, manufactured by Amersham Pharmacia Biotech).

#### Prehybridization

Reaction solution: ExpressHyb (manufactured by Clontech Laboratories, Inc.)

Reaction temperature: 68°C

Reaction time: 30 minutes

#### Hybridization

Reaction solution: ExpressHyb (manufactured by Clontech Laboratories, Inc.)

<sup>32</sup>P labeled cDNA probe:  $1 \times 10^6$  cpm/ml

Reaction temperature: 68°C

Reaction time: 1 hour

6) The membrane after the hybridization was washed with the solution as described below according to the protocols for ExpressHyb (manufactured by Clontech Laboratories, Inc.)

2 × SSC, 0.05 % SDS 500 ml

Room temperature

Time: 40 minutes

0.1 × SSC, 0.1 % SDS

50°C

Time: 40 minutes

7) The washed nylon membrane was exposed to X-ray film (e.g., XAR 5 film manufactured by Eastman Kodak Company) overnight at -80°C to take autoradiographs.

8) Positions of positive plaques were determined based on the resulting autoradiographs, and then phages in the corresponding plaques on the agar were recovered in an SM solution.

9) The recovered phages were again allowed to form plaques on a NZY agar medium by a standard method, and then immobilized on a nylon membrane.

10) Procedures 5) to 9) were repeated 3 times to obtain unified phages in positive plaques. The phages were collected and suspended in 500 μl of SM solution. The suspension was added with 20 μl of chloroform and stirred to prepare a phage



solution. cDNA isolated from the phage solution contained sheep and bovine epimorphin genes.

## 2. Preparation of sheep and bovine epimorphin cDNA in large quantity

1) 10  $\mu$ l of the phage solution suspended in the SM solution, 200  $\mu$ l of XL1-Blue Escherichia coli (manufactured by STRATAGENE), and 1  $\mu$ l of helper phages (manufactured by STRATAGENE) were mixed and allowed to react for 15 minutes at 37°C.

2) The mixed solution was then transferred in 3 ml of LB medium, and the medium was shake-cultured overnight at 37°C to cleave and recover the genes as pBluescript phagemid.

3) The phagemid was treated for 20 minutes at 70°C and centrifuged at 1000 rpm for 15 minutes, and then the supernatant was recovered.

4) 100  $\mu$ l of the supernatant and 200  $\mu$ l of SOLR Escherichia coli were mixed, and then the mixture was allowed to react for 15 minutes at 37°C.

5) 10  $\mu$ l of the solution obtained in 4) was inoculated over a plate of LB medium containing 50  $\mu$ g/ml of ampicillin, and then the plate was cultured overnight at 37°C.

6) One colony was added to 3 ml of an LB medium containing 50  $\mu$ g/ml of ampicillin, and then the medium was shake-cultured overnight at 37°C.

7) The culture product was centrifuged at 2000 rpm for 10 minutes to recover the E. coli.

8) The E. coli was purified using a Plasmid Mini Kit (manufactured by QIAGEN) to prepare plasmid DNA containing sheep or bovine epimorphin genes in a large quantity.

## 3. Sequencing of sheep and bovine epimorphin cDNA

The entire nucleotide sequences of sheep and bovine epimorphin genes in the plasmid DNA were determined by the dye terminator method using an auto sequencer.

## 4. Determination of amino acid sequences

Amino acid sequences of sheep and bovine epimorphin were determined based on the nucleotide sequences determined in the above step 3 (Genetics-Mac provided by Software Development Co., Ltd. was used as a computer software for this step).

Each of the amino acid sequences was named; sheep epimorphin 2, bovine epimorphin 2, and bovine epimorphin 4.

#### 5. Preparation of transformants

cDNA of each of sheep epimorphin 2, bovine epimorphin 2, and bovine epimorphin 4 was inserted into pBluescript SK(-) plasmid, and then the plasmid was introduced in Escherichia coli strain SOLR to obtain transformants. The resulting respective transformants were named as Sh-EPM2, Bo-EPM2, and Bo-EPM4.

#### Industrial Applicability

The protein of the present invention can exert epimorphin-like biological activities including, for example, differentiation of milk protein-producing cells into branched luminal structure, and promotion of hair growth. The protein of the present invention can be used as a medicament for Artiodactyls or as an agent for modifying animal properties. For example, the protein of the present invention enlarges the mammary glands of Artiodactyls including cows and sheep to prevent the gland from clogging, thereby an yield of a desired protein secreted in the milk of the animal is increased. Furthermore, sheep for a high productivity of wool and transgenic animals (an animal factory) for a high productivity of a target protein can be generated by using the gene of the present invention.

What is claimed is:

1. A protein comprising any one of the amino acid sequences set forth in SEQ ID NOS: 1, 3, and 5 in the Sequence Listing.

2. A protein having 95% or more homology to an amino acid sequence from the 1st to 262nd amino acids of the amino acid sequence set forth in SEQ ID NO:1 in the Sequence Listing.

3. The protein according to Claim 2 having an amino acid sequence from the 1st to 262nd amino acids of the amino acid sequence set forth in SEQ ID NO: 1 in the Sequence Listing.

4. The protein according to Claim 2 having an amino acid sequence from the 1st to 262nd amino acids of the amino acid sequence set forth in SEQ ID NO: 5 in the Sequence Listing.

5. A protein having any one of the amino acid sequences set forth in SEQ ID NOS: 1, 3, and 5 in the Sequence Listing wherein one or more amino acids are substituted, deleted or added; and inducing differentiation of a milk protein-producing cell into a branched luminal structure.

6. A protein in which one or more amino acids are substituted, deleted, and/or added in an amino acid sequence defined by the 1st to 262nd amino acids of either of the amino acid sequence set forth in SEQ ID NOS: 1 or 5 in the Sequence Listing, which has 95 % or more homology to the amino acid sequence defined by the 1st to 262nd amino acids of either of the amino acid sequence set forth in SEQ ID NO: 1 or 5 and induces differentiation of a milk protein-producing cell into a branched luminal structure.

7. A protein having any one of the amino acid sequences set forth in SEQ ID NOS: 1, 3, and 5 in the Sequence Listing wherein one or more amino acids are substituted, deleted or added; and promoting hair growth.

8. A protein in which one or more amino acids are substituted, deleted, and/or added in an amino acid sequence defined by the 1st to 262nd amino acids of either of the amino acid sequence set forth in SEQ ID NOS: 1 or 5 in the Sequence Listing, which has 95 % or more homology to the amino acid sequence defined by the 1st to 262nd amino acids of either of the amino acid sequence set forth in SEQ ID NO: 1 or 5

and promotes hair growth.

9. A polynucleotide encoding the protein according to any one of claims 1 to 8.

10. A polynucleotide according to claim 9, which is a DNA set forth in SEQ ID NO: 2, 4 or 6.

11. An antibody recognizing the protein according to any one of claims 1 to 8.

## Declaration and Power of Attorney For Utility or Design Patent Application

## 特許出願宣言書

## Japanese Language Declaration

私は、下欄に氏名を記載した発明者として、以下のとおり  
宣言する：

私の住所、郵便の宛先および国籍は、下欄に氏名に続いて記載したとおり  
であり、

名称の発明に関し、請求の範囲に記載した特許を求める主題の本来の、  
最初にして唯一の発明者である(一人の氏名のみが下欄に記載されている  
場合)か、もしくは本来の、最初にして共同の発明者である(複数の氏名が  
下欄に記載されている場合)と信じ、

上記発明の明細書(下記の欄でX印がついていない場合は、  
本書に添付)は、

☐ 年 月 日に提出され、  
米国出願番号 \_\_\_\_\_ とし、  
(該当する場合) 年 月 日に訂正されました。又は、  
特許協定条約国際出願番号 \_\_\_\_\_ とし、  
(該当する場合) 年 月 日に訂正されました。

私は、前記のとおり補正した請求の範囲を含む前記明細書の内容を検討し、  
理解したことを陳述する。

私は、連邦規則法典第37編第1条第56項に定義されるとおり、特許資  
格の有無について重要な情報を開示すべき義務があることを認めます。

私は合衆国法典第35部第119条(a-d)項又は第365条(b)項に基づく、下  
記の外国特許出願又は発明者証出願、或いは第365条(a)項に基づく、少な  
くとも米国以外の1ヶ国を指名したPCT国際出願の外国優先権を主張し、  
更に優先権の主張に係わる基礎出願の出願日前の出願日を有する外国特許  
出願、又は発明者証出願或いはPCT国際出願を以下に“なし”の箱に印を  
つけることにより明記する：

Prior foreign applications

先の外国出願

233892/1998

(Number)  
(番号)

Japan

(Country)  
(国名)

August 20, 1998

(Day/Month/Year Filed)  
(出願の年月日)

(Number)  
(番号)

(Country)  
(国名)

(Day/Month/Year Filed)  
(出願の年月日)

☐ その他の外国特許出願番号は別紙の追補優先権欄にて記載する。

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated  
below next to my name.

I believe I am the original, first and sole inventor (if only one name is  
listed below) or an original, first and joint inventor (if plural names  
are listed below) of the subject matter which is claimed and for  
which a patent is sought on the invention entitled

EPIMORPHIN OF THE ORDER ARTIODACTYLA

the specification of which is attached hereto unless the following  
box is checked:

☒ was filed on August 20, 1999 as  
United States Application Number 09/744,989  
and was amended on 2/16/2001 (if applicable) or,  
PCT International Application Number PCT/JP99/04479  
and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents  
of the above identified specification, including the claims, as  
amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to  
patentability as defined in Title 37, Code of Federal Regulations,  
§1.56.

I hereby claim foreign priority under Title 35, United States Code  
§119(a-d) or §365(b) of any foreign application(s) for patent or  
inventor's certificate, or §365(a) of any PCT international application  
which designated at least one country other than the United States,  
listed below. I have also identified below, by checking the "No"  
box, any foreign application for patent or inventor's certificate, or of  
any PCT international application having a filing date before that of  
the application on which priority is claimed:

Priority claimed  
優先権の主張

<input checked="" type="checkbox"/>	<input type="checkbox"/>
Yes	No
あり	なし
<input type="checkbox"/>	<input type="checkbox"/>
Yes	No
あり	なし

☐ Additional foreign application numbers are listed on a  
supplemental priority sheet attached hereto.

# Japanese Language Utility or Design Patent Application Declaration

私は、合衆国法典第35部第119条(e)項に基づく、下記の合衆国仮特許出願の利益を主張する。

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

(Application No.)  
(出願番号)

(Day/Month/Year Filed)  
出願の年月日

(Application No.)  
(出願番号)

(Day/Month/Year Filed)  
出願の年月日

(Application No.)  
(出願番号)

(Day/Month/Year Filed)  
出願の年月日

☐ その他の合衆国仮特許出願番号は別紙の追補優先権欄にて記載する。

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

私は、合衆国法典第35部第120条に基づく下記の合衆国特許出願、又は第365条(c)項に基づく合衆国を指名したPCT国際出願の利益を主張し、本願の請求の範囲各項に記載の主題が合衆国法典第35部第112条第1項規定の態様で、先の合衆国特許出願又はPCT国際出願に開示されていない限度において、先の出願の出願日と本願の国内出願日又はPCT国際出願日の間に有効となった連邦規則法典第37部第1章第56条に記載の特許要件に所要の情報を開示すべき義務を有することを認める。

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

(Application No.)  
(出願番号)

(Day/Month/Year Filed)  
(出願の年月日)

(現況)  
(特許済み、係属中 放棄済み)

(Status)  
(patented, pending, abandoned)

(Application No.)  
(出願番号)

(Day/Month/Year Filed)  
(出願の年月日)

(現況)  
(特許済み、係属中 放棄済み)

(Status)  
(patented, pending, abandoned)

☐ その他の合衆国又は国際特許出願番号は別紙の追補優先権欄にて記載する。

☐ Additional U.S. or international application numbers are listed on a supplemental priority sheet attached hereto.

私は、ここに自己の知識にもとずいて行った陳述がすべて真実であり、自己の有する情報および信ずるところに従って行った陳述が真実であると信じ、さらに故意に虚偽の陳述等を行った場合、合衆国法典第18部第1001条により、罰金もしくは禁錮に処せられるか、またはこれらの刑が併科され、またかかる故意による虚偽による陳述が本願ないし本願に対して付与される特許の有効性を損なうことがあることを認識して、以上の陳述を行ったことを宣言する。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

私、下記署名者は、ここに記載の米国弁護士または代理人に本出願に関し特許商標庁にて取られるいかなる行為に関して、同米国弁護士又は代理人が、私に直接連絡なしに私の外国弁護士或いは法人代表者からの指示を受け取り、それに従うようここに委任する。この指示を出す者が変更の場合には、ここに記載の米国弁護士又は代理人にその旨通知される。

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from either his foreign patent agent or corporate representative, if any, as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

## Japanese Language Utility or Design Patent Application Declaration

委任状： 私は、下記発明者として、下記に明記された顧客番号を伴う以下の弁護士又は、代理人をここに選任し、本順の手続きを遂行すること並びにこれに関する一切の行為を特許商標庁に対して行うことを委任する。そして全ての通信はこの顧客番号宛に発送される。

顧客番号 7055

現在選任された弁護士は下記の通りである。

Neil F. Greenblum Reg. No. 28,394  
 Bruce H. Bernstein Reg. No. 29,027  
 James L. Rowland Reg. No. 32,674  
 Arnold Turk Reg. No. 33,094

POWER OF ATTORNEY: As a named inventor, I hereby appoint the attorney(s) and/or agent(s) associated with the Customer Number provided below to prosecute this application and transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

**CUSTOMER NUMBER 7055**

The appointed attorneys presently include:

Stephen M. Roylance Reg. No. 31,296  
 William E. Lyddane Reg. No. 41,568  
 William Pieprz Reg. No. 33,630  
 Leslie J. Paperner Reg. No. 33,329

Address: **GREENBLUM & BERNSTEIN, P.L.C.**

1941 ROLAND CLARKE PLACE  
 RESTON, VA 20191

直接電話連絡先：(名称および電話番号)

Direct Telephone Calls to: (name and telephone number)

**GREENBLUM & BERNSTEIN, P.L.C.**

(703) 716-1191

唯一のまたは第一の発明者の氏名	Full name of sole or first inventor <u>Keiko TSUGANEZAWA</u>	
同発明者の署名	日付 <u>1-0</u>	Inventor's signature <u>Keiko Tsuganezawa</u> Date <u>Apr. 16, 2001</u>
住所	Residence <u>Yokohama Kanagawa, JAPAN JPX</u>	
国籍	Citizenship Japan	
郵便の宛先	Post Office Address c/o Yokohama Works of Sumitomo Electric Industries, Ltd., 1, Taya-cho Sakae-ku, Yokohama-shi, Kanagawa 244-8588	
第2の共同発明者の氏名 (該当する場合)	Full name of second joint inventor, if any	
同第2共同発明者の署名	日付	Second Inventor's signature Date
住所	Residence	
国籍	Citizenship	
郵便の宛先	Post Office Address	

(第6またはそれ以降の共同発明者に対しても同様な情報および署名を提供すること。)

(Supply similar information and signature for third and subsequent joint inventors.)

Sequence Listing

<110> Sumitomo Electric Industries, Co., Ltd.

<120> Artiodactyla epimorphin

<130> 99044M

<160> 6

<210> 1

<211> 287

<212> PRT

<213> Bos

<400> 1

Met Arg Asp Arg Leu Pro Asp Leu Thr Ala Cys Arg Lys Asn Asp Asp

5 10 15

Gly Asp Thr Thr Val Val Val Glu Lys Asp His Phe Met Asp Asp Phe

20 25 30

Phe His Gln Val Glu Glu Ile Arg Asn Ser Ile Ala Lys Ile Ala Gln

35 40 45

Tyr Val Glu Glu Val Lys Lys Asn His Ser Ile Ile Leu Ser Ala Pro

50 55 60

Asn Pro Glu Gly Lys Ile Lys Glu Glu Leu Glu Asp Leu Asn Lys Glu

65 70 75 80

Ile Lys Lys Thr Ala Asn Lys Ile Arg Thr Lys Leu Lys Ser Ile Glu

85 90 95

Gln Ser Phe Asp Gln Asp Glu Gly Gly Asn Arg Thr Ser Val Glu Leu

100 105 110

Arg Ile Arg Arg Thr Gln His Ser Val Leu Ser Arg Lys Phe Val Glu

115 120 125



Val Met Thr Glu Tyr Asn Glu Ala Gln Thr Leu Phe Arg Glu Arg Ser

130

135

140

Lys Gly Arg Ile Gln Arg Gln Leu Glu Ile Thr Gly Lys Thr Thr Thr

145

150

155

160

Asp Asp Glu Leu Glu Glu Met Leu Glu Ser Gly Asn Pro Ser Ile Phe

165

170

175

Thr Ser Asp Ile Ile Ser Asp Ser Gln Ile Thr Arg Gln Ala Leu Asn

180

185

190

Glu Ile Glu Ser Arg His Lys Asp Ile Met Lys Leu Glu Thr Ser Ile

195

200

205

Arg Glu Leu His Glu Met Phe Met Asp Met Ala Met Phe Val Glu Thr

210

215

220

Gln Gly Glu Met Ile Asn Asn Ile Glu Lys Asn Val Met Asn Ala Ala

225

230

235

240

Asp Tyr Val Glu His Ala Lys Glu Glu Thr Lys Lys Ala Ile Lys Tyr

245

250

255

Gln Ser Lys Ala Arg Arg Lys Met Met Phe Ile Ile Ile Cys Val Val

260

265

270

Ile Leu Leu Val Ile Leu Gly Ile Ile Leu Ala Thr Thr Leu Ser

275

280

285

<210> 2

<211> 864

<212> DNA

<213> Bos

<400> 2

ATG CGG GAC CGG CTG CCG GAC CTG ACG GCG TGT AGG AAA AAT GAT GAT

48

GGG GAC ACA ACT GTT GTT GTT GAA AAG GAC CAT TTT ATG GAT GAT TTC

96

TTC CAT CAG GTC GAG GAG ATC AGA AAC AGT ATA GCG AAA ATA GCT CAG 144  
 TAT GTC GAA GAA GTG AAG AAA AAC CAC AGC ATC ATT CTT TCT GCA CCA 192  
 AAC CCA GAA GGA AAA ATA AAG GAA GAG CTT GAA GAT CTG AAC AAA GAA 240  
 ATC AAG AAA ACT GCT AAT AAA ATA AGG ACT AAG TTG AAG TCT ATT GAA 288  
 CAG AGT TTT GAT CAG GAT GAG GGT GGA AAC CGA ACT TCT GTG GAG CTT 336  
 CGG ATA CGA AGA ACC CAG CAT TCA GTG CTA TCT CGA AAG TTT GTG GAA 384  
 GTC ATG ACA GAA TAT AAC GAA GCA CAG ACT CTG TTT CGG GAG CGA AGC 432  
 AAA GGC CGT ATA CAG CGT CAG CTA GAA ATA ACT GGA AAA ACT ACC ACC 480  
 GAT GAT GAG CTG GAA GAG ATG CTG GAA AGT GGG AAT CCC TCC ATC TTC 528  
 ACG TCA GAT ATT ATA TCA GAT TCA CAA ATT ACT AGA CAG GCT CTC AAT 576  
 GAA ATT GAG TCC CGT CAT AAA GAC ATC ATG AAG CTG GAG ACA AGC ATC 624  
 CGT GAG CTA CAT GAG ATG TTC ATG GAC ATG GCC ATG TTC GTC GAG ACT 672  
 CAG GGT GAA ATG ATC AAC AAC ATA GAA AAA AAT GTT ATG AAT GCC GCA 720  
 GAC TAT GTA GAA CAT GCA AAA GAA GAA ACG AAG AAA GCT ATT AAA TAT 768  
 CAA AGC AAA GCA AGA AGG AAA ATG ATG TTC ATT ATT ATT TGT GTA GTT 816  
 ATT TTG CTT GTG ATC CTT GGA ATT ATC CTA GCA ACA ACA TTG TCA TAG 864

<210> 3

<211> 269

<212> PRT

<213> Bos

<400> 3

Met Arg Asp Arg Leu Pro Asp Leu Thr Ala Cys Arg Lys Asn Asp Asp

5

10

15

Gly Asp Thr Thr Val Val Val Glu Lys Asp His Phe Met Asp Asp Phe

20

25

30

Phe His Gln Val Glu Glu Ile Arg Asn Ser Ile Ala Lys Ile Ala Gln

35

40

45

Tyr Val Glu Glu Val Lys Lys Asn His Ser Ile Ile Leu Ser Ala Pro  
 50 55 60  
 Asn Pro Glu Gly Lys Ile Lys Glu Glu Leu Glu Asp Leu Asn Lys Glu  
 65 70 75 80  
 Ile Lys Lys Thr Ala Asn Lys Ile Arg Thr Lys Leu Lys Ser Ile Glu  
 85 90 95  
 Gln Ser Phe Asp Gln Asp Glu Gly Gly Asn Arg Thr Ser Val Glu Leu  
 100 105 110  
 Arg Ile Arg Arg Thr Gln His Ser Val Leu Ser Arg Lys Phe Val Glu  
 115 120 125  
 Val Met Thr Glu Tyr Asn Glu Ala Gln Thr Leu Phe Arg Glu Arg Ser  
 130 135 140  
 Lys Gly Arg Ile Gln Arg Gln Leu Glu Ile Thr Gly Lys Thr Thr Thr  
 145 150 155 160  
 Asp Asp Glu Leu Glu Glu Met Leu Glu Ser Gly Asn Pro Ser Ile Phe  
 165 170 175  
 Thr Ser Asp Ile Ile Ser Asp Ser Gln Ile Thr Arg Gln Ala Leu Asn  
 180 185 190  
 Glu Ile Glu Ser Arg His Lys Asp Ile Met Lys Leu Glu Thr Ser Ile  
 195 200 205  
 Arg Glu Leu His Glu Met Phe Met Asp Met Ala Met Phe Val Glu Thr  
 210 215 220  
 Gln Gly Glu Met Ile Asn Asn Ile Glu Lys Asn Val Met Asn Ala Ala  
 225 230 235 240  
 Asp Tyr Val Glu His Ala Lys Glu Glu Thr Lys Lys Ala Ile Lys Tyr  
 245 250 255  
 Gln Ser Lys Ala Arg Arg Val Ser Leu Val Phe Gln Ser

&lt;210&gt; 4

&lt;211&gt; 810

&lt;212&gt; DNA

&lt;213&gt; Bos

&lt;400&gt; 4

ATG CGG GAC CGG CTG CCG GAC CTG ACG GCG TGT AGG AAA AAT GAT GAT	48
GGG GAC ACA ACT GTT GTT GTT GAA AAG GAC CAT TTT ATG GAT GAT TTC	96
TTC CAT CAG GTC GAG GAG ATC AGA AAC AGT ATA GCG AAA ATA GCT CAG	144
TAT GTC GAA GAA GTG AAG AAA AAC CAC AGC ATC ATT CTT TCT GCA CCA	192
AAC CCA GAA GGA AAA ATA AAG GAA GAG CTT GAA GAT CTG AAC AAA GAA	240
ATC AAG AAA ACT GCT AAT AAA ATA AGG ACT AAG TTG AAG TCT ATT GAA	288
CAG AGT TTT GAT CAG GAT GAG GGT GGA AAC CGA ACT TCT GTG GAG CTT	336
CGG ATA CGA AGA ACC CAG CAT TCA GTG CTA TCT CGA AAG TTT GTG GAA	384
GTC ATG ACA GAA TAT AAC GAA GCA CAG ACT CTG TTT CGG GAG CGA AGC	432
AAA GGC CGT ATA CAG CGT CAG CTA GAA ATA ACT GGA AAA ACT ACC ACC	480
GAT GAT GAG CTG GAA GAG ATG CTG GAA AGT GGG AAT CCC TCC ATC TTC	528
ACG TCA GAT ATT ATA TCA GAT TCA CAA ATT ACT AGA CAG GCT CTC AAT	576
GAA ATT GAG TCC CGT CAT AAA GAC ATC ATG AAG CTG GAG ACA AGC ATC	624
CGT GAG CTA CAT GAG ATG TTC ATG GAC ATG GCC ATG TTC GTC GAG ACT	672
CAG GGT GAA ATG ATC AAC AAC ATA GAA AAA AAT GTT ATG AAT GCC GCA	720
GAC TAT GTA GAA CAT GCA AAA GAA GAA ACG AAG AAA GCT ATT AAA TAT	768
CAA AGC AAA GCA AGA AGG GTG AGT TTG GTC TTT CAG AGT TGA	810

&lt;210&gt; 5

&lt;211&gt; 287

&lt;212&gt; PRT

&lt;213&gt; Ovis

<400> 5

Met Arg Asp Arg Leu Pro Asp Leu Thr Ala Cys Arg Lys Asn Asp Asp  
1 5 10 15  
Gly Asp Thr Thr Val Val Val Glu Lys Asp His Phe Met Asp Asp Phe  
20 25 30  
Phe His Gln Val Glu Glu Ile Arg Asn Ser Ile Ala Lys Ile Ala Gln  
35 40 45  
Tyr Val Glu Glu Val Lys Lys Asn His Ser Ile Ile Leu Ser Ala Pro  
50 55 60  
Asn Pro Glu Gly Lys Ile Lys Glu Glu Leu Glu Asp Leu Asn Lys Glu  
65 70 75 80  
Ile Lys Lys Thr Ala Asn Lys Ile Arg Thr Lys Leu Lys Ser Ile Glu  
85 90 95  
Gln Ser Phe Asp Gln Asp Glu Gly Gly Asn Arg Thr Ser Val Glu Leu  
100 105 110  
Arg Ile Arg Arg Thr Gln His Ser Val Leu Ser Arg Lys Phe Val Glu  
115 120 125  
Val Met Thr Glu Phe Asn Glu Ala Gln Thr Leu Phe Arg Glu Arg Ser  
130 135 140  
Lys Gly Arg Ile Gln Arg Gln Leu Glu Ile Thr Gly Lys Thr Thr Thr  
145 150 155 160  
Asp Asp Glu Leu Glu Glu Met Leu Glu Ser Gly Asn Pro Ser Ile Phe  
165 170 175  
Thr Ser Asp Ile Ile Ser Asp Ser Gln Ile Thr Arg Gln Ala Leu Asn  
180 185 190  
Glu Ile Glu Ser Arg His Lys Asp Ile Met Lys Leu Glu Thr Ser Ile  
195 200 205

Arg Glu Leu His Glu Met Phe Met Asp Met Ala Met Phe Val Glu Thr  
210 215 220  
Gln Gly Glu Met Ile Asn Asn Ile Glu Lys Asn Val Thr Asn Ala Ala  
225 230 235 240  
Asp Tyr Val Glu His Ala Lys Glu Glu Thr Lys Lys Ala Ile Lys Tyr  
245 250 255  
Gln Ser Lys Ala Arg Arg Lys Met Met Phe Ile Ile Ile Cys Val Val  
260 265 270  
Ile Leu Leu Val Ile Phe Gly Ile Ile Leu Ala Thr Thr Leu Ser  
275 280 285

<210> 6

<211> 864

<212> DNA

<213> Ovis

<400> 6

ATG CGG GAC CGG CTG CCG GAC CTG ACG GCG TGT AGG AAA AAT GAT GAT	48
GGG GAC ACA ACT GTT GTT GTT GAA AAG GAC CAT TTT ATG GAT GAT TTC	96
TTC CAT CAG GTC GAG GAG ATC AGA AAC AGT ATA GCA AAA ATA GCT CAG	144
TAT GTC GAA GAA GTG AAG AAA AAC CAC AGC ATC ATT CTT TCT GCA CCA	192
AAC CCA GAA GGA AAA ATA AAG GAA GAG CTT GAA GAT CTG AAC AAA GAA	240
ATC AAG AAA ACT GCC AAT AAA ATT CGG ACT AAG TTG AAG TCT ATT GAA	288
CAG AGT TTT GAT CAG GAT GAG GGT GGA AAC CGA ACT TCT GTG GAG CTT	336
CGG ATA CGA AGA ACC CAG CAT TCA GTG CTA TCT CGA AAG TTT GTG GAA	384
GTC ATG ACA GAA TTT AAT GAA GCA CAG ACT CTG TTT CGG GAG CGA AGC	432
AAA GGC CGT ATA CAG CGT CAG CTA GAA ATA ACT GGA AAA ACT ACC ACC	480
GAT GAT GAG CTG GAA GAG ATG CTG GAA AGT GGG AAT CCC TCC ATC TTC	528
ACG TCA GAT ATT ATA TCA GAT TCA CAA ATC ACT AGA CAG GCT CTG AAT	576

GAA ATT GAG TCC CGT CAT AAA GAC ATC ATG AAG CTG GAG ACG AGC ATC	624
CGT GAG CTG CAC GAG ATG TTC ATG GAC ATG GCC ATG TTC GTC GAG ACC	672
CAG GGT GAA ATG ATC AAC AAC ATA GAA AAA AAT GTT ACG AAT GCC GCA	720
GAC TAT GTT GAG CAT GCT AAA GAA GAA ACG AAG AAA GCC ATT AAA TAT	768
CAA AGC AAA GCA AGA AGG AAA ATG ATG TTC ATT ATT ATC TGT GTA GTT	816
ATT TTG CTT GTG ATC TTT GGA ATT ATC CTA GCA ACA ACA TTG TCA TAG	864